SYRE
Spyre TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
SYRE vs peer average
63/100
SYRE vs. peer average (B vs. C)
Grade spread
A 2 · B 2 · C 2 · D 4
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
NTLA is the first available peer comparator.
Genome-editing therapeutics company with binary clinical catalysts and elevated event-driven volatility—relevant for risk‑premium assessment.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
SYRE
Spyre Therapeutics
NTLA
Intellia Therapeutics
Grade
B
D
Momentum
97
17
Value
41
41
Sentiment
31
65
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs NTLA
SYRE / NTLA
Grade Position
In line
SYRE vs. peer average (B vs. C)
63/100
Momentum
97
SYREValue
41
SYRESentiment
31
NTLARotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs SYRE
NTLA is the first peer returned for this comparison set.